Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
Gilead’s Pivot to NASH Hits a Snag as Its Drug Flunks Phase III Trial
The 2019 pipeline report: Changing the treatment paradigm
A Talk With Robert Jacks, New CEO of NASH and Fibrotic Drugmaker Indalo
Is the Smoldering NASH Market Ready to Burst Into Flames?
The 20 Hottest Pipeline Drugs to Watch in 2019
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential … Continue Reading NASH Pipelines Face Questions as Drugs Near Potential Approval